AstraZeneca: Update On US Food And Drug Administration Emergency Use Authorization Of EVUSHELD
January 27, 2023
January 27, 2023
WILMINGTON, Delaware, Jan. 27 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
The US Food and Drug Administration (FDA) has stated that AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab) is not currently authorized for Emergency Use for pre-exposure prophylaxis (prevention) of COVID-19 in the US until further notice, due to the sustained high frequency of circulating SARS-CoV-2 variants that EVUSHELD does not retain in vitr . . .
The US Food and Drug Administration (FDA) has stated that AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab) is not currently authorized for Emergency Use for pre-exposure prophylaxis (prevention) of COVID-19 in the US until further notice, due to the sustained high frequency of circulating SARS-CoV-2 variants that EVUSHELD does not retain in vitr . . .